CAMBRIDGE, Mass.--(BUSINESS WIRE)-- FierceBiotech today named Foundation Medicine, Inc. as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection. This company is fast. In just two years Foundation Medicine has developed a diagnostic test that helps investigators manage the fast-changing genetic information needed in clinical research and gives physicians a better tool to make some rational decisions on the drugs they choose to treat cancer victims, says FierceBiotech Editor John Carroll. Its drawn the backing of some high-profile tech investors like Google Ventures. And, a lineup of cancer drug developers has signed on to work with the company on key cancer drug programs. We are honored to be named to the 2012Fierce15and believe this award is a testament to the progressFoundationMedicine continues to make toward our vision of transforming cancer care through the development of our fully informative genomic profile, said Michael J. Pellini, M.D., president and chief executive officer ofFoundationMedicine. The Fierce 15 celebrates the spirit of being fierce championing innovation and creativity, even in the face of intense competition. An internationally recognized daily newsletter reaching more than 100,000 biotech and … Continue reading →

Queenstown Regenerative Medicine - http://www.queenstownRM.co.nz Professor Richard Boyd and Dr Dan Bates Latest developments of Stem Cell Therapy and Regenerative Medicine Queenstown Regenerative Medicine, in association with Monash University Immunology and Stem Cell Centre (MISCL), has the pleasure of requesting your attendance at an evening lecture by Prof Richard Boyd, Head of MISCL and Dr Dan Bates, Sports Medicine Physician from Melbourne AFL Club. Professor Richard Boyd is a world leader in the research and development of potential uses of stem cells to treat disease in both human and animal. He is the Director of Australia's largest and most prestigious Stem Cell Laboratory and a recipient of numerous International Awards for unique research into how stem cells and the immune system develop and how they have their effects in the body. Professor Boyd's talk will give an overall background to stem cells and the work going on around the world to put these cellular therapies and regenerative medicine into the clinic. Doctor Dan Bates is a Sports Medicine Physician working with Professor Boyd in the development and use of cellular medicine applications in the field of Sports Medicine and musculoskeletal injuries. Dan is the current team doctor of the Melbourne … Continue reading →

JERUSALEM--(BUSINESS WIRE)-- Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the companys second pipeline product. NiCord is in development as an experimental treatment for a series of indications that potentially could be cured with a bone marrow transplantation including hematological malignancies (blood cancer), sickle cell disease, thalassemia, severe autoimmune diseases and metabolic diseases. The clinical trial announced today (clinicaltrials.gov identifier NCT01221857) is studying NiCord as an alternative investigational treatment for hematological malignancies (HM). A combined total of 11 patients were transplanted at Duke University Medical Center and at Loyola University Medical Center. Dr. Mitchell E. Horwitz of Duke University Medical Center is the principal investigator. Final results of the Phase I/II study are expected within 6 months. The company is also actively enrolling for a Phase I/II study of NiCord as an experimental treatment for sickle cell, a genetic blood disease (clinicaltrials.gov identifier NCT01590628). NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology. As the Phase I/II trial for HM is … Continue reading →

PHILADELPHIA, Sept. 19, 2012 /PRNewswire/ --With the eyes of the world firmly fixed on Stockholm and the upcoming announcement of the 2012 Nobel Prize recipients, the IP & Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, announced its 2012 "Nobel-class" Citation Laureates today. Annually, Thomson Reuters citation analysts mine proprietary data from the company's research platform, Web of Knowledge, to identify the most influential researchers in the categories of chemistry, physics, physiology or medicine, and economics. Based on a thorough review of citations to their research, the company names these high-impact researchers as Thomson Reuters Citation Laureates and predicts them to be Nobel Prize winners, either this year or in the future. "Our Citation Laureate selection process operates much like the Nobel Foundation's selection process," said David Pendlebury, Thomson Reuters citation analyst. "We recognize fundamental discoveries and identify the most important contributors to these discoveries. Our Citation Laureates have made such important contributions to science that we believe them to be peers of the Nobel Prize winners in every way; they simply have yet to win." The Citation Laureates rank among the top one-tenth of one percent (0.1%) of researchers in their fields … Continue reading →

The Department of Tourism plans to add another reason for more visitors to come to the country through a soon-to-be drafted medical tourism plan, which highlights the relatively cheap yet world-class health services some of the countrys hospitals have to offer. In this proposed plan, DOT Secretary Ramon Jimenez aims to get the countrys medical sector to put its best foot forward by highlighting stem cell therapy as well as other areas of specialization. Medical tourism focuses on some very serious, important areas of healthcare that the world will travel for, Jimenez said during a forum on stem cell science conducted at the Medical City hospital in Pasig City on Tuesday evening. Through promoting world-class medical services in the country, such as some of Philippine hospitals stem cell programs, Jimenez said the DOT aims to draw foreigners into the country who, in his words, yung sasakay sila ng eroplano, tatawid sila ng dagat. (Foreigners) would obviously spend less if they sought care in their own country like the United States or (places in) Europe. So you really have to have a value that will mitigate the cost of that travel. Your service has to be superior, greater value for their … Continue reading →